J Cancer 2022; 13(8):2584-2593. doi:10.7150/jca.69583 This issue Cite

Research Paper

Transketolase Serves as a Biomarker for Poor Prognosis in Human Lung Adenocarcinoma

Cong Niu*, Wenjia Qiu*, Xiangyang Li, Hongqing Li, Ji'an Zhou, Huili Zhu

Department of Respiratory Medicine, Huadong Hospital, Fudan University, Shanghai, China
*Cong Niu and Wenjia Qiu both first authors, shared common contribution.

Citation:
Niu C, Qiu W, Li X, Li H, Zhou J, Zhu H. Transketolase Serves as a Biomarker for Poor Prognosis in Human Lung Adenocarcinoma. J Cancer 2022; 13(8):2584-2593. doi:10.7150/jca.69583. https://www.jcancer.org/v13p2584.htm
Other styles

File import instruction

Abstract

Graphic abstract

Despite apparently having completed surgical resection, approximately half of resected early-stage lung cancer patients relapse and die of their disease. Adjuvant chemotherapy reduces this risk by only 5% to 8%. Thus, there is a need for better identifying the drivers of relapse, who benefits from adjuvant therapy, and novel targets in this setting. Although emerging evidence has suggested a strong link between the pentose phosphate pathway (PPP) and cancer, the role of transketolase (TKT), an enzyme in the nonoxidative branch of the PPP that connects PPP and glycolysis, remains obscure in Lung adenocarcinoma (LUAD). In this study, TKT expression was first identified in The Cancer Genome Atlas (TCGA) and then validated with our database. TKT was upregulated at protein levels in cancer compared with normal tissues (P <0.05), and high TKT expression was associated with advanced tumor stage in our cohorts. Besides, TKT inhibitor promotes tumor cell apoptosis and cell cycle blockade. Clearly, TKT plays a critical role in LUAD progression and prognosis and could be a potential biomarker for prediction of recurrence after lung cancer resection.

Keywords: Transketolase, lung adenocarcinoma, prognosis, biomarker


Citation styles

APA
Niu, C., Qiu, W., Li, X., Li, H., Zhou, J., Zhu, H. (2022). Transketolase Serves as a Biomarker for Poor Prognosis in Human Lung Adenocarcinoma. Journal of Cancer, 13(8), 2584-2593. https://doi.org/10.7150/jca.69583.

ACS
Niu, C.; Qiu, W.; Li, X.; Li, H.; Zhou, J.; Zhu, H. Transketolase Serves as a Biomarker for Poor Prognosis in Human Lung Adenocarcinoma. J. Cancer 2022, 13 (8), 2584-2593. DOI: 10.7150/jca.69583.

NLM
Niu C, Qiu W, Li X, Li H, Zhou J, Zhu H. Transketolase Serves as a Biomarker for Poor Prognosis in Human Lung Adenocarcinoma. J Cancer 2022; 13(8):2584-2593. doi:10.7150/jca.69583. https://www.jcancer.org/v13p2584.htm

CSE
Niu C, Qiu W, Li X, Li H, Zhou J, Zhu H. 2022. Transketolase Serves as a Biomarker for Poor Prognosis in Human Lung Adenocarcinoma. J Cancer. 13(8):2584-2593.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image